Seer (NASDAQ:SEER) Director Dipchand Nishar Sells 10,660 Shares of Stock

Posted by George Bondi on Jul 11th, 2026

Seer, Inc. (NASDAQ:SEER – Get Free Report) Director Dipchand Nishar sold 10,660 shares of Seer stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $2.18, for a total transaction of $23,238.80. Following the sale, the director owned 59,044 shares in the company, valued at $128,715.92. This represents a 15.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Seer Stock Down 1.4%

SEER traded down $0.03 on Friday, reaching $2.17. The company had a trading volume of 300,631 shares, compared to its average volume of 2,158,689. Seer, Inc. has a 1 year low of $1.55 and a 1 year high of $2.41. The stock has a market capitalization of $119.31 million, a PE ratio of -1.75 and a beta of 1.59. The stock has a 50-day moving average price of $1.81 and a 200-day moving average price of $1.84.

Seer (NASDAQ:SEER – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.30). Seer had a negative return on equity of 26.58% and a negative net margin of 464.78%.The company had revenue of $2.79 million for the quarter, compared to analyst estimates of $3.60 million.

Institutional Investors Weigh In On Seer

Hedge funds have recently made changes to their positions in the business. Occudo Quantitative Strategies LP purchased a new position in shares of Seer during the second quarter worth about $25,000. Marshall Wace LLP purchased a new stake in Seer during the 4th quarter valued at approximately $85,000. Quadrature Capital Ltd acquired a new stake in Seer during the 4th quarter worth approximately $101,000. Barclays PLC lifted its position in Seer by 685.0% during the 4th quarter. Barclays PLC now owns 60,717 shares of the company’s stock worth $111,000 after acquiring an additional 52,982 shares during the period. Finally, Marquette Asset Management LLC purchased a new position in shares of Seer in the 2nd quarter valued at approximately $103,000. Institutional investors and hedge funds own 75.20% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on SEER shares. Weiss Ratings restated a “sell (d-)” rating on shares of Seer in a research note on Tuesday, April 21st. Canaccord Genuity Group initiated coverage on Seer in a research note on Monday, May 4th. They issued a “buy” rating and a $4.00 price objective for the company. Finally, TD Cowen raised Seer to a “strong-buy” rating in a report on Monday, April 13th. Two research analysts have rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $4.00.

View Our Latest Report on SEER

About Seer

(Get Free Report)

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.